GBP Capital News

Dec 16, 2008

MabVax Therapeutics Receives Two Small Business Technology Transfer Program Awards From The National Cancer Institute

San Diego, CA, December 16, 2008 -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, announced the company has received two grant awards from t Read More...

Filed Under: GBP Captial News

Dec 04, 2008

Lentigen and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza

Seattle, WA and Gaithersburg, MD, December 4, 2008—The biotech company Lentigen Corporation and the nonprofit global health organization PATH announced today a partnership to accelerate research on a pandemic influenza vaccine. PATH will initially invest $3 million over 27 months and wo Read More...

Filed Under: GBP Captial News

Oct 01, 2008

Lentigen Corporation and the United States Army Agree to Contract

GAITHERSBURG, Md., Oct 01, 2008 /PRNewswire via COMTEX/ -- Lentigen Corporation announced today that it has established a contract with the United States Army to extend the programs established in the initial agreement announced in 2006. This contract is for a further phase of Lentigen Corpor Read More...

Filed Under: GBP Captial News

Aug 14, 2008

Flexible Stenting Solutions Announces Successful Completion of First-in-Man Study of Third Generation Peripheral Arterial Stent

Eatontown , NJ - Flexible Stenting Solutions Inc., a leading developer of third generation peripheral arterial stents, announced today that a physician at Auckland City Hospital in New Zealand successfully implanted several of its third generation arterial Read More...

Filed Under: GBP Captial News

Aug 12, 2008

MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research

San Diego, CA, August 12, 2008 -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of two separate licensing Read More...

Filed Under: GBP Captial News

May 19, 2008

HyperMed, Inc. Receives Additional $4 Million from GBP Capital

Burlington, MA – May 19, 2008 – HyperMed, Inc., the leader in hyperspectral medical imaging, today announces it completed $4 million financing from GBP Capital (GBP) this month. Proceeds will support ongoing marketing and sales of OxyVu™, its lead product. Mark Carbeau Read More...

Filed Under: GBP Captial News

Feb 27, 2008

MabVax Therapeutics Closes $8 Million Series A Financing with GBP Capital

Greenwich, CT and San Diego, CA February 27, 2008 -- MabVax Therapeutics Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion o Read More...

Filed Under: GBP Captial News

Dec 20, 2007

GBP IP, LLC Acquires Lentiviral Gene Delivery Technology from Cell Genesys

Cell Genesys, Inc. (Nasdaq: CEGE) and GBP IP, LLC, an affiliate of GBP Capital, the majority shareholder in privately held Lentigen Corporation, today announced that the two companies have entered into an asset sale agreement relating to Cell Genesys' lentiviral gene delivery technology, commonl Read More...

Filed Under: GBP Captial News

8 results: